Jessica Orf
Principal Scientist II Gilead Sciences
Jessica Orf is a Principal Scientist II at Gilead Sciences, where she leads the Oncology in vivo pharmacology group. Jessica specializes in oncology mouse models. Her team supports in vivo pharmacology research across Gilead’s oncology pipeline, contributing to the development of diverse therapeutic modalities including small molecules, biologics, and cell therapies.
Seminars
Thursday 29th January 2026
Roundtable Discussion: Providing Guidance to In Vitro Modelling Standards for Toxicity to Align with FDA Expectation & Good Laboratory Practice
2:45 pm
- Exploring FDA perspectives on in vitro toxicology to clarify requirements for advancing ADCs, T cell engagers, and cell therapies into clinical trials
- Designing robust in vitro models to generate translational safety data and address regulatory uncertainty in emerging therapeutic modalities
- Refining assay strategies and safety endpoints to strengthen FDA confidence in preclinical packages while minimizing reliance on animal studies
Thursday 29th January 2026
Roundtable Discussion: Exploring the Translatability & Reproducibility of In Vitro, In Vivo, Ex Vivo & In Silico Approaches to Improve Clinical Predictability
1:00 pm
- Comparing diverse preclinical model systems (in vitro, in vivo, ex vivo and in silico) to establish a comprehensive framework for translational relevance
- Identifying model-specific challenges and adaptive strategies to enhance reliability, overcome experimental limitations and model variability
- Optimizing the combination and number of models to accurately forecast therapeutic responses in clinical settings
Wednesday 28th January 2026
Chair’s Opening Remarks
8:25 am
Thursday 29th January 2026
Chair’s Opening Remarks
8:55 am
